Latest Headlines

Latest Headlines

UPDATED: Arena shares sink after biotech withdraws marketing app for obesity drug in Europe

Arena Pharmaceuticals pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and regulatory effort behind the treatment. The San Diego-based biotech revealed the decision to withdraw the app in its first-quarter financial report late Thursday afternoon.

UPDATED: FDA hits green light on Vivus weight drug Qnexa

The FDA has given a green light to Vivus to start marketing its weight drug Qnexa, firing the starting pistol in a race to commercialize one of the first new obesity drugs in 13 years.

Quick enrollment may speed Orexigen obesity drug study

Orexigen ($OREX) says that it's enrollment of patients in a closely-watched safety study of its weight drug Contrave is happening much faster than expected.

Slate of looming FDA decisions keeps M&A watchers on high alert

Biotech investors have a busy FDA schedule to ponder for the month ahead. Adam Feuerstein at TheStreet highlights four big drug decisions in the weeks to come, and he's bullish about the chances of some closely-watched drugs.

Arena basks in spotlight as FDA OKs obesity drug lorcaserin

More than a year of second-guessing and harsh criticism for Arena Pharmaceuticals concluded with a big victory for the drug developer, which earned an FDA approval for lorcaserin, the first new weight drug to hit the U.S. market in 13 long years.

The cliffhanger: FDA set to decide on Arena's lorcaserin

The biotech investment community is on high alert today, waiting for word of the FDA's formal decision on Arena Pharmaceutical's application for its weight drug lorcaserin.

UPDATED: Arena Pharma's weight drug wins the day, shares soar

A committee of non-agency advisers backed approval of the weight drug, lorcaserin, which went down in flames when last in front of the same panel in 2010.

All eyes in the biotech world on Arena's diet pill

Biotech industry watchers are paying close attention to an FDA advisory committee today that will judge the biotech's drug, lorcaserin.

UPDATED: Arena shares up after FDA briefing on lorcaserin

Oddsmakers are watching the FDA advisory committee that will consider lorcaserin this week very closely.

Vivus shares slide as FDA delays decision on Qnexa

Shares of Vivus slid more than 6% after the news spread that the FDA would delay a final decision on its closely watched application for the weight drug Qnexa.